Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

Transaction summary

Key questions

• How does this disposition impact the insider's full economical exposure?
  While the merchantability liquidated 83% of nonstop communal stock, William Guyer retains a important equity involvement done 130,000 derivative securities held straight successful the signifier of banal options.

• What was the underlying mechanics for the transaction?
  This was a pre-scheduled transaction executed nether a Rule 10b5-1 trading program established connected November 27, 2024, providing a cooling-off play good beyond regulatory minimums.

• Are determination circumstantial restrictions tied to the remaining nonstop equity?
  Of the 3,985 shares held directly, 1,599 shares are tied to unvested restricted banal awards granted betwixt December 2025 and June 2026.

Company Overview

Company Snapshot

• Corcept Therapeutics is simply a pharmaceutical institution that discovers, develops, and commercializes treatments for superior metabolic, oncological, and neuropsychiatric disorders, with Korlym (mifepristone) tablets arsenic its superior commercialized merchandise for treating endogenous Cushing's syndrome successful big patients.

• The institution generates gross done the nonstop commercialization and merchantability of its pharmaceutical products to healthcare providers and patients, leveraging its proprietary cause improvement and regulatory expertise successful specialized therapeutic areas.

• Corcept's superior customers are hospitals, specialty pharmacies, and idiosyncratic patients with diagnosed endocrine and metabolic disorders, peculiarly those requiring attraction for Cushing's syndrome and related conditions.

Corcept Therapeutics is simply a specialized pharmaceutical institution that maintains a focused commercialized strategy centered connected its pb therapeutic asset, Korlym, which addresses a important unmet aesculapian request successful the attraction of endogenous Cushing's syndrome. With 730 employees and operations headquartered successful Menlo Park, California, Corcept has demonstrated beardown marketplace performance, with its banal appreciating 39% implicit the past year, reflecting capitalist assurance successful its pipeline and commercialized execution.